TP53 and B-cell chronic lymphocytic leukemia: However, even in 2024, the assessment of IGHV status and TP53 aberrations at CLL diagnosis is still not recommended in the daily routine outside of clinical trials [4] and has not been broadly available at our institution before 2010.